Showing results (21-30 of 79) with videos related to
Sort By:
Pageof 8
Breast (Edinburgh, Scotland)|August 27, 2013
Scalp cooling to prevent alopecia after chemotherapy can be considered safe in patients with breast cancerC J G van den Hurk, L V van de Poll-Franse, W P M Breed, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patientsS J T Jansen, W Otten, M C M Baas-Thijssen, et al.British Journal of Cancer|September 18, 2008
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer GroupD M Kweekel, M Koopman, N F Antonini, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2005
Endocrine treatment options for advanced breast cancer--the role of fulvestrantJ F R Robertson, S E Come, S E Jones, et al.Breast (Edinburgh, Scotland)|October 1, 2016
Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperatureM M C Komen, C H Smorenburg, J W R Nortier, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 8, 2012
Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The NetherlandsL N van Steenbergen, V E P P Lemmens, H J T Rutten, et al.Cancer Treatment Reviews|July 30, 2013
Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic reviewA Charehbili, D B Y Fontein, J R Kroep, et al.Cancer Chemotherapy and Pharmacology|December 12, 2012
The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levelsF L Opdam, V O Dezentje, J den Hartigh, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 27, 2016
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)D B Y Fontein, A Charehbili, J W R Nortier, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2015
Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trialD B Y Fontein, M Klinten Grand, J W R Nortier, et al.Pageof 8